Form 4: Director Shao-Ta Lu Executes RSU Vesting at YD Bio
Statement of Changes in Beneficial Ownership
Director Shao-Ta Lu acquired 2,081 ordinary shares of YD Bio Ltd through the vesting of restricted share units.
Summary
- Director Shao-Ta Lu acquired 2,081 ordinary shares of YD Bio Ltd on March 31, 2026.
- The acquisition resulted from the vesting of restricted share units (RSUs) granted under the company's Equity Incentive Plan.
- The total grant value for the RSUs was $60,000, with quarterly vesting installments of $15,000 each.
- Following the transaction, the director holds 2,081 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market-moving implications.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Transparent disclosure of executive compensation and equity vesting schedules.
Negatives
- None identified in this filing.
Risks
- Future share price volatility may impact the number of shares issued upon subsequent RSU vesting dates, as the number of shares is determined by a volume-weighted average price calculation.
Future Outlook
The RSUs vest in four equal quarterly installments, with the number of shares determined by the volume-weighted average price of the company's shares prior to each vesting date.
Industry Context
StockSavvy.ai notes that this filing represents standard corporate governance practice for equity-based compensation of board members in the biotechnology sector, ensuring long-term alignment between leadership and company performance.
Comparison to Industry Standards
- The use of quarterly vesting schedules for director equity is consistent with standard corporate governance practices for publicly traded companies.
- The reliance on volume-weighted average price (VWAP) for determining share issuance is a common mechanism to mitigate the impact of short-term market volatility on executive compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Implementation of RSU vesting schedule for Director Shao-Ta Lu. | 03/31/2026 | Neutral; standard alignment of director incentives. |
Stakeholder Impact
- Shareholders: Minimal impact; reflects standard director compensation practices.
Next Steps
- Future quarterly vesting of remaining RSUs under the Equity Incentive Plan.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of RSU grant, vesting, and acquisition of ordinary shares. |
| 04/02/2026 | Date of filing for the Form 4 statement. |
Keywords
YD Bio, YDES, Form 4, Insider Trading, Restricted Share Units, Equity Incentive Plan, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.